Document Detail


Coronary artery bypass grafting after aprotinin: Are we doing better?
MedLine Citation:
PMID:  23072702     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVE: Cardiac surgery patients are treated with antifibrinolytic agents to reduce intra- and postoperative bleeding. Until 2007, lysine analogues (aminocaproic acid and tranexamic acid) and serine protease inhibitors (aprotinin) were recommended. In 2008, the U.S. Food and Drug Administration prohibited aprotinin use because of associated postoperative complications, including cerebrovascular accidents and renal failure. This work aimed at reevaluating the efficacy and safety of aprotinin versus tranexamic acid in patients undergoing elective coronary artery bypass surgery. METHODS: Two groups were enrolled in this study. Group A (n = 256), operated from January 2005 to August 2007, was treated with the half-Hammersmith aprotinin regime whereas group B (n = 104), operated after 2008, was treated with the full-dose tranexamic acid regime. All patients were of low-risk profile, and underwent an elective, on-pump coronary artery bypass surgery. The main outcome measures were safety, assessed in relation to thrombosis-related cardiac, cerebral, and renal events; and efficacy, investigated in terms of postoperative bleeding and infusions of blood products. RESULTS: Postoperatively, group B demonstrated greater bleeding during the operative and first postoperative days, and total bleeding (P values ≤ .001); a greater requirement of blood and/or blood products infusions (P = .024); higher postoperative acute renal failure rates (P = .028); lower platelet count (P = .002); and a higher postoperative increase in troponin levels (P < .0001). CONCLUSIONS: Among low-risk patients undergoing coronary artery bypass surgery, the half-Hammersmith aprotinin-based antifibrinolytic management proved to be more efficacious in terms of bleeding and consumption of blood products, with no evidence of associated increased rates of postoperative complications. Accordingly, the usage of aprotinin should be reconsidered for treatment among cohorts of low-risk cardiac patients.
Authors:
Ziv Beckerman; Yoni Shopen; Hagar Alon; Oved Cohen; Rony-Reuven Nir; Zvi Adler; Gil Bolotin
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-13
Journal Detail:
Title:  The Journal of thoracic and cardiovascular surgery     Volume:  -     ISSN:  1097-685X     ISO Abbreviation:  J. Thorac. Cardiovasc. Surg.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0376343     Medline TA:  J Thorac Cardiovasc Surg     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Affiliation:
Department of Cardiac Surgery, Rambam Health Care Campus, Haifa, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Behaviour of co-inoculated pathogenic and spoilage bacteria on poultry following several decontamina...
Next Document:  Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis.